Medicare’s cap on monthly #insulin costs reduced beneficiaries’ spending on the drug by 21% and increased use among those who previously had especially high costs, finds new USC Schaeffer research in JAMA.
The monthly spending limit improved adherence among insulin users who previously had especially high costs, Schaeffer researchers found. - June 8, 2026
